Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim vs Filgrastim for Neutropenia in Breast Cancer
NCT01611051Phase 3Completed
- Sponsor
- Hengrui
- Start
- Mar 2012
- Primary completion
- Jan 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mecapegfilgrastim in neutropenia (3 arms), sponsored by Hengrui. Primary endpoint: Rate and the duration of grade 3/4 neutropenia in cycle 1. Started Mar 2012; status: completed.
02
Drugs
mecapegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT01611051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611051.